Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
Compugen (CGEN) has announced promising data on the triple combination of COM701, COM902, and pembrolizumab in treating platinum-resistant ovarian cancer patients. The data will be presented at the SITC 2024 conference in Houston, Texas. The study showed a 17.4% confirmed objective response rate and a 43.5% disease control rate in 23 evaluable patients.
The treatment demonstrated a favorable safety profile with mostly Grade 2 or lower adverse events, and only one Grade 3 event reported. Dr. Oladapo Yeku from Harvard Medical School highlighted the treatment's durability and effectiveness in late-stage ovarian cancer patients. The company plans to advance COM701 to earlier stages of ovarian cancer therapy, particularly targeting patients who are ineligible for maintenance treatment.
Compugen (CGEN) ha annunciato dati promettenti sulla combinazione tripla di COM701, COM902 e pembrolizumab nel trattamento di pazienti con carcinoma ovarico resistenti al platino. I dati saranno presentati alla conferenza SITC 2024 a Houston, Texas. Lo studio ha mostrato un tasso di risposta obiettiva confermato del 17,4% e un tasso di controllo della malattia del 43,5% in 23 pazienti valutabili.
Il trattamento ha dimostrato un profilo di sicurezza favorevole, con principalmente eventi avversi di Grado 2 o inferiori, e solo un evento di Grado 3 riportato. Il Dr. Oladapo Yeku della Harvard Medical School ha evidenziato la durata e l'efficacia del trattamento in pazienti con carcinoma ovarico in fase avanzata. L'azienda prevede di avanzare COM701 a fasi precedenti della terapia per il carcinoma ovarico, mirata in particolare a pazienti che non sono idonei per il trattamento di mantenimento.
Compugen (CGEN) ha anunciado datos prometedores sobre la combinación triple de COM701, COM902 y pembrolizumab en el tratamiento de pacientes con cáncer de ovario resistente a platino. Los datos se presentarán en la conferencia SITC 2024 en Houston, Texas. El estudio mostró una tasa de respuesta objetiva confirmada del 17.4% y una tasa de control de la enfermedad del 43.5% en 23 pacientes evaluables.
El tratamiento demostró un perfil de seguridad favorable, con mayormente eventos adversos de Grado 2 o inferiores, y solo un evento de Grado 3 reportado. El Dr. Oladapo Yeku de la Facultad de Medicina de Harvard destacó la durabilidad y efectividad del tratamiento en pacientes con cáncer de ovario en etapas avanzadas. La empresa planea avanzar COM701 a etapas más tempranas de la terapia para el cáncer de ovario, apuntando particularmente a pacientes que no son elegibles para el tratamiento de mantenimiento.
Compugen (CGEN)은 백금 내성 난소암 환자를 치료하기 위한 COM701, COM902 및 pembrolizumab의 삼중 조합에 대한 유망한 데이터를 발표했습니다. 데이터는 텍사스주 휴스턴에서 열리는 SITC 2024 회의에서 발표될 예정입니다. 연구에서 23명의 평가 가능한 환자 중 17.4%의 확인된 객관적 반응률과 43.5%의 질병 조절률이 나타났습니다.
치료는 대부분 2등급 이하의 부작용이 나타나는 우호적인 안전성 프로필을 보여주었으며, 3등급의 부작용은 하나만 보고되었습니다. 하버드 의대의 올라도포 예쿠 박사는 후기 난소암 환자에서 치료의 지속성과 효과를 강조했습니다. 이 회사는 COM701을 난소암 치료의 초기 단계로 진전시킬 계획이며, 특히 유지 치료가 적합하지 않은 환자를 목표로 하고 있습니다.
Compugen (CGEN) a annoncé des données prometteuses sur la combinaison triple de COM701, COM902 et pembrolizumab dans le traitement des patientes atteintes de cancer de l'ovaire résistant au platine. Les données seront présentées lors de la conférence SITC 2024 à Houston, Texas. L'étude a montré un taux de réponse objective confirmé de 17,4% et un taux de contrôle de la maladie de 43,5% chez 23 patientes évaluables.
Le traitement a démontré un profil de sécurité favorable, avec principalement des événements indésirables de grade 2 ou moins, et un seul événement de grade 3 signalé. Le Dr Oladapo Yeku de l'École de Médecine de Harvard a souligné la durabilité et l'efficacité du traitement chez les patientes atteintes de cancer de l'ovaire à un stade avancé. L'entreprise prévoit de faire avancer COM701 vers des stades antérieurs de la thérapie du cancer de l'ovaire, ciblant en particulier les patientes inéligibles pour un traitement d'entretien.
Compugen (CGEN) hat vielversprechende Daten zur dreifachen Kombination von COM701, COM902 und Pembrolizumab bei der Behandlung von platinresistenten Ovarialkrebspatientinnen veröffentlicht. Die Daten werden auf der SITC 2024 Konferenz in Houston, Texas, vorgestellt. Die Studie zeigte eine bestätigte objektive Ansprechrate von 17,4% und eine Krankheitskontrollrate von 43,5% bei 23 auswertbaren Patientinnen.
Die Behandlung wies ein günstiges Sicherheitsprofil auf, mit hauptsächlich Grad 2 oder niedrigeren unerwünschten Ereignissen und nur einem berichteten Grad 3 Ereignis. Dr. Oladapo Yeku von der Harvard Medical School hob die Nachhaltigkeit und Wirksamkeit der Behandlung bei Patientinnen mit fortgeschrittenem Ovarialkarzinom hervor. Das Unternehmen plant, COM701 in frühere Stadien der Ovarialkrebstherapie zu bringen, insbesondere bei Patientinnen, die für eine Erhaltungstherapie nicht geeignet sind.
- None.
- None.
HOLON,
This data and additional clinical data will be presented by Oladapo Yeku, M.D., Ph.D., FACP, Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program, Massachusetts General Hospital,
"The data from this study along with data Compugen previously presented, demonstrate that COM701 is active, has a favorable safety profile, and is a differentiated immune checkpoint inhibitor. COM701 in combination with COM902 (Fc reduced anti-TIGIT) and pembrolizumab (anti-PD-1) resulted in durable objective responses in late-stage ovarian cancer patients typically not responsive to other immunotherapeutic agents," said Dr. Oladapo Yeku. "There is a significant unmet need for effective, durable, and tolerable treatment options for patients with relapsed ovarian cancer. I look forward to discussing this data in
Anat Cohen-Dayag, Ph.D. President, and Chief Executive Officer of Compugen added, "We are highly encouraged by the consistency of the data between our two platinum resistant ovarian cancer studies demonstrating COM701 driven activity and safety profile in more than forty advanced and heavily pre-treated patients. We believe these data support our initial observation of the unique mechanism of action of COM701 translating into clinical benefit in patients with ovarian cancer. We are encouraged by feedback from ovarian cancer experts supporting advancing COM701 to an earlier setting of ovarian cancer therapy based on its overall activity, safety profile and durability demonstrated in advanced disease. There is a gap in care for women with platinum sensitive ovarian cancer, who respond to chemotherapy but are ineligible for or cannot tolerate additional maintenance treatment. These patients have a less compromised immune system, providing the opportunity to harness the unique mechanism of action of COM701 to potentially change the disease trajectory improving progression free survival."
Dr. Cohen-Dayag continued, "Our development path in earlier lines of ovarian cancer will start by addressing this unmet need. I look forward to discussing these data and our future development plans including a fireside chat with Dr. Yeku, as part of our third quarter conference call that will take place on November 12, 2024, at 8:30 am ET."
The abstract is now available on the publication section of Compugen's website. The poster and short video presentation of the poster by Dr. Yeku will be available on the publication section of Compugen's website on Friday November 8, 2024.
SITC 2024 abstract Data cut off: May 16, 2024 Note: The poster to be presented at SITC on November 8, 2024 will include additional data | |
Treatment | COM701+COM902+pembrolizumab |
No. patients | 23 (efficacy evaluable) |
Confirmed ORR | |
Confirmed DCR | 43.5 % |
Immune activation | Increase in peripheral IFNg |
Safety | Majority AEs GR ≤2 No GR 4/5 AEs 1 GR 3 event, serious immune related encephalopathy resolving following treatment with steroids |
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements relating to our belief that the unique mechanism of action of COM701 may have a clinical benefit in patients with ovarian cancer; statement relating to the potential of COM701 to change the disease trajectory and improving progression free survival; statements relating to the target of our development path in earlier lines of ovarian cancer; and statements regarding our plans to provide details of our plans for further development of COM701 during our third quarter conference call These and other forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties, and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen's approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value; the general market, political and economic conditions in the countries in which Compugen operates, including
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:SOURCE Compugen Ltd.
FAQ
What are the clinical results of COM701 combination therapy in platinum resistant ovarian cancer?
What is the safety profile of COM701 combination therapy presented at SITC 2024?
When and where will Compugen (CGEN) present the COM701 combination therapy data?
What are Compugen's (CGEN) future plans for COM701 in ovarian cancer treatment?
